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Abstract 
High  resistance  and  recurrence  rates,  along  with  elevated  drug  clearance, 
compel the use of maximum tolerated drug doses in cancer therapy, resulting in 
high-grade toxicities and limited clinical applicability. Promoting active drug 
accumulation in tumor tissues would minimize such issues and improve 
therapeutic outcomes. A new class of therapeutic drugs suitable for the task has 
emerged based on the concept of virus-mimetic nanocarriers, or ‘artificial viruses.’ 
Among the spectrum of materials under exploration in nanocarrier research, 
proteins offer unparalleled structural and functional versatility for designing virus-
like molecular vehicles. By exhibiting ‘smart’ functions and biomimetic traits, 
protein-based nanocarriers will be a step ahead of the conventional drug-protein 
conjugates already in the clinics in ensuring efficient delivery of passenger anti-
tumor drugs. 
 
 
 
Protein nanoparticles; Drug delivery; Biomaterials; Biomimetics; Protein 
engineering; Targeted therapy
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Drug-based cancer therapies 
 
Since age is a main factor of risk, the high prevalence of cancer in high-income 
countries places this disease as a second highest cause of death (around 1 in 4 
deaths), after cardiovascular diseases [1]. Despite possible compensatory effects 
of early detection, the high mortality among cancer patients stresses the 
limitation of current treatments, many of which are essentially based on surgery 
and adjuvant chemotherapy [2]. Low molecular weight cytotoxic chemicals, such 
as 5-Fluorouracil, Cisplatin or Doxorubicin have been developed and used for 
decades and they represent the current basis of treatment for most cancers [3]. 
These drugs induce DNA damage, leading to tumor cell death, and are 
administered at maximum tolerated doses. The resulting high systemic drug 
levels cause severe toxicities related to DNA damage in highly proliferative 
healthy tissues (e.g. bone marrow), which worsens patients’ quality of life [4]. 
Poor drug penetration due to abnormal tumor architecture and composition [5], 
and clearance through hepatic metabolism [6] or renal clearance (with a cut-off 
around 7 nm; see Glossary) [7] are additional factors that hamper a desired dose 
reduction to safer, less toxic values. 
 
 
 
Renal filtration can be largely minimized by increasing the molecular size of the 
drug, through conjugation to large molecules such as proteins, which act as 
carriers. In addition to allowing longer circulation times in the bloodstream, drug- 
protein conjugation reduces hepatic clearance and increases drug concentration 
in tumors, compared to free-drug administration. This is because its nanometric 
size promotes higher nanoconjugate accumulation in tumor tissue because of the 
enhanced permeability retention (EPR) effect; that is, a form of passive targeting 
[8;9] (Box 1). In this regard, nab-paclitaxel has been incorporated into treatment 
regimens for advanced breast, lung or pancreatic cancer. In nab-paclitaxel, the
4  
bound albumin stabilizes paclitaxel and in effect increases the size of the drug. 
Because of the many possible benefits of having drugs that are larger than small 
molecules, nanoparticles (usually ranging from 10 to 100 nm) are promising 
agents in the development of cancer therapies [10]. Most nanoparticles currently 
used in the clinic exhibit passive targeting (e.g. liposomal doxorubicin, nab- 
paclitaxel)  [11]. In  this  context, only about  5  % of  the  injected  therapeutic 
reaches the tumor because the high accumulation (50-80 % of the dose) of 
nanoparticles in the mononuclear phagocytic system (MPS) especially in the liver 
[12-14]. This process could be attenuated through the covalent attachment of 
polyethylene glycol (PEGylation) to the nanoparticle [15] (Box 1). However, the 
penetration of nab-paclitaxel into tumors might also benefit from indirect effects. 
Thus, the albumin component of the nanoparticle may bind to SPARC, a protein 
secreted by stromal fibroblasts to the tumor extracellular space, or to the gp60 
receptor, facilitating nab-paclitaxel endothelial transcytosis [16;17]. 
 
 
 
Cell targeting in cancer treatments 
 
A relevant and distinctive property of cancer tissues is that the proteins that 
drive tumor progression, such as cytokine, hormone or grow factor receptors are 
differentially overexpressed in cancer stem cells (CSC), as compared to healthy 
tissues [18]. Such differential expression can enable the molecular tagging of 
cancer cells for the delivery of next generation drugs. Molecular tags are already 
implemented in  combination  with  conventional  therapies  to  inhibit  signalling 
from a specific target protein (eg, VEGF, EGFR, HER-2 or B-Raf) [19]. Although 
less aggressive than in chemotherapy, toxicity can also arise if target activity is 
inhibited  in  normal  tissues,  and  resistance  can  develop  through  target  or 
pathway mutation (e.g. EGFR amplification) or the activation of alternative or 
compensatory pathways [18].
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Learning from these lessons, cell targeting in cancer treatment should be 
primarily exploited to engineer the biodistribution of conventional, well-known 
drugs as cargos in long-circulating nanoconjugates, aimed to increase the 
effective drug concentration in tumor cells. In this regard, if the administered 
drugs would be introduced in such a way that they only (or preferentially) 
penetrate tumor cells, doses could be largely reduced and toxicity issues 
essentially minimized. CSCs are responsible for tumor and metastasis initiation 
and maintenance and closely associated with aggressiveness. Active drug 
targeting aimed at eliminating CSCs is then a promising anticancer strategy. This 
therapeutic   approach   takes   advantage   of   the   differential   expression   of 
membrane receptors between CSCs and the bulk of the tumor, mainly composed 
of differentiated cells [20]. 
 
 
 
Proteins, virus-like functions and artificial viruses 
 
In  nature,  animal  viruses,  which  are  nanoscale  in  size,  exhibit  exquisite 
specificity for cell surface receptors displayed on target cells. The specific 
interactions that trigger infection are mediated by cross-molecular interactions 
between peptide motifs in capsid proteins that act as ligands, and target surface 
cell proteins that act as receptors for the virus. The multivalency of ligand- 
receptor  binding based on  the  repetitive and regular  architecture of  viruses 
ensures  a  high  degree  of  tissue  and  cell  penetrability,  and  increases  the 
likelihood of interaction. In parallel, an increasing number of peptides and protein 
domains have been described as tumor-homing peptides. They exhibit the ability 
to specifically bind cell-surface protein markers in CSCs or in more differentiated 
cells [21-23], with an important degree of discrimination between specific tumor 
types  [24].  Alternatively,  nonspecific  cell-penetrating  peptides  have  been
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engineered to be activated by local stimuli, such as low pH, or by 
metaloproteases, which are present in tumor tissues [25]. 
 
 
 
All these categories of peptides are valuable tools in enabling the targeting of 
drugs   to   specific   tumors   or   tumor   cell   sub-populations,   provided   they 
functionalize nano-sized vehicles in a multivalent and regular distribution. The 
‘artificial virus’ concept was proposed to define any manmade biocompatible 
nanomaterial exhibiting virus-like characteristics and size, with the potential to 
be cell-targeted carriers in molecular therapies [26]. Metals, polymers, carbon 
nanotubes or lipids may be suitable for nanoparticle fabrication [27]. However, 
proteins are likely the most convenient materials for the construction of effective 
viral mimetics in therapy, since they are the ultimate supporters of biological 
functions and specificity in molecular interactions. Being fully biocompatible, 
proteins have been produced since decades in cell factories by cost-effective 
scalable bioproduction (or by chemical synthesis if short peptides), to be used, 
among other applications, as pharmaceuticals [28;29]. In this regard, the 
regulatory issues linked to the administration of proteins to humans have been 
already well addressed, and the number of endotoxin-free and generically 
recognized as safe (GRAS) microorganisms available for biological production of 
proteins is lately expanding [30]. In addition, precise protein engineering by 
conventional genetic approaches allows the modulation of their functional and 
structural properties in a very versatile way. 
 
 
 
Furthermore, cost-effective large-scale production of difficult-to-express proteins 
and nanostructured protein materials is now becoming feasible due to 
accumulating advances in genetics and systems biotechnology [31;32] and the 
increasing availability of cell factories adapted to complex protein production
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challenges [30;33;34]. The multiple virus-like functions necessary for molecular 
transport  and  intracellular  delivery  can  only  be  achieved  by  proteins,  and 
different functions can be assumed by protein complexes of by the construction 
of single chain modular polypeptides that recruit diverse functional domains from 
independent origins [35]. The unique functional and structural plasticity of 
proteins is ideal for the generation of multifunctional vehicles adapted to the 
targeted transportation of specific drug types, including nucleic acids (in non- 
viral gene therapy) and chemicals (in chemotherapy). Although protein-based 
viral mimetics have great potential for use in cancer therapy [36], rapid 
development of therapeutic artificial viruses has been unfortunately impaired by 
still limited structural comprehension of protein-protein interactions and by the 
lack  of  universal  tools  to  predict  and  engineer  precise  contacts  between 
designed polypeptides. The ability to arrange building blocks in regular patterns 
to generate multivalent constructs of defined nanoscale size, is an unavoidable 
requirement for the de novo generation of virus-like assemblies. Although control 
over particle size has been more easily reached in the design of liposomes and 
related polymer-based vehicles, the issue is much more challenging in the case 
of protein vehicles. Some recent successes in the computing-assisted design of 
complex protein nanostructures [37;38] permit to envisage, however, the 
feasibility of tailoring multimeric protein nanomaterials. 
 
 
 
Emerging nanoarchitectonic principles, viral mimetics and antitumoral 
drug delivery 
In this context, protein science has benefited from multiple approaches to 
engineering protein self-assembly [36;39], which have resulted in the generation 
of a wide range of nanoparticles and nanostructured materials [40]. The most 
promising routes to reach functional protein nanoparticles include: exploitation of
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the amphiphillic character of peptides and proteins, the adaptation of natural 
oligorimerization  domains  and  the  manipulation  of  charge  distribution  to 
modulate electrostatic protein-protein interactions (Table 1). A fraction of these 
constructs tend to mimic viral features through the self-organization of 
multifunctional building blocks in virus-like assemblies, within the viral size range 
and with regular or filamentous morphologies (Figure 1). Among such constructs, 
those empowered with protein segments that bind cancer cell markers display 
specificity  for  cancer  cells  in  vitro  and  reach  tumor  tissues  in  vivo,  thus 
promoting a desired biodistribution map while avoiding renal filtration [41]. The 
repetitive nature of the building blocks in both spherical and filamentous 
nanoparticles allows for a multivalent display of cell ligands. The multivalent and 
regular ligand display in artificial viruses favours cell binding and endosomal- 
mediated uptake, as is the case in natural viruses, e.g. human rhinovirus 14 
particles, which bind to different molecules of the cell surface receptor ICAM-1 
(Figure 1 H). When loaded with conventional anti-tumor drugs, drug stability is 
often enhanced and the specificity and efficacy of cell killing is dramatically 
improved in comparison to soluble free drugs (Table 1). Some multifunctional 
proteins of this kind have already entered clinical trials [42]. 
 
 
 
In a paradigmatic example of viral mimetics, multifunctional single chain proteins 
were developed based on the linear fusion of three main cassettes: an amino 
terminal cationic peptide, a core scaffold protein and a carboxy terminal 
polyhistidine  [43].  Such  an  engineering  scheme  is  extremely  efficient  in 
promoting   the   self-organization   of   the   whole   chimera   under   aqueous 
physiological conditions [41], as nanoparticles of regulatable size between 10 
and 80 nm [44]. This is irrespective of the particular scaffold protein used as 
building  block  core,  and  the  particular  amino  acid  sequence  of  the  amino
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terminal segment. These constructs are stable in vivo and escape renal filtration, 
exhibiting a high degree cellular penetrability both in cell culture and  in vivo 
[41;45-47]. The regular disposition of the building blocks as planar toroid entities 
(Figure 1) [41] ensures a symmetric presentation of functional motifs on the 
particle surface. When the carboxy terminal region of the building block 
corresponds to a cancer relevant ligand, such as the tumor homing peptides T22 
and A5 (which bind the cancer cell markers CXCR4 and CD44 respectively), high 
cell specificity has been achieved both in cell culture and in vivo [41;46;47]. T22- 
empowered CXCR4-targeted protein nanoparticles penetrated CXCR4+   cells in 
both primary tumor and metastatic foci in colorectal cancer mice models [46;48]. 
It is already possible to load artificial viruses with expressible DNA for gene 
delivery [48]. Coupling artificial viruses to anti-tumor compounds would be a 
logical next step. 
 
 
 
Concluding remarks and future perspectives. 
 
In summary, the versatility of protein engineering regarding structure and 
function  offers  unique  opportunities  for  the  construction  of  viral  mimetics 
adapted to targeted drug delivery in molecular cancer therapies. Long-term 
experience in the biofabrication of enzymes and protein drugs ensures cost- 
effective large-scale biofabrication under GMP and the overcoming of any 
regulatory constraint for clinical use. Surpassing other materials of common use 
in  Nanotechnology,  self-assembling  peptides  and  proteins  are  exceptional 
building blocks that allow efficient design and fabrication of biocompatible 
artificial viruses for the treatment of cancer. These entities can then be tailored 
to overcome the current limitations of chemotherapy associated with poor 
effectiveness and toxicity, by promoting longer circulation time and enhancing 
selective delivery of the cargo drug into target cancer cells. The rapidly growing
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list of tumor-homing peptides and the refining of nano-architectonic protein 
engineering principles has already generated excitement for first-generation 
prototypes in the still nascent area of artificial virus design. Although these viral 
mimetics can be loaded with conventional chemical drugs or nucleic acids, the 
versatile nature of their protein building blocks makes them fully adaptable to 
any next generation passenger drug that might be incorporated into the clinical 
use in the future. 
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Legends 
 
 
 
 
Figure 1. Diverse categories of drug-loadable protein-based artificial viruses 
resulting from the self-assembling of repetitive building blocks. (A): E2 protein- 
based   nanoparticles formed by 60 repetitive units and with an hydrodynamic 
size of around 33 nm. Reproduced with permission from [49]. (B): Decameric, 
GFP-based 13 nm-nanoparticles organized in a star-shaped distribution, that 
display the efficient CXCR4 ligand T22. Reproduced with permission from [41]. 
(C): Modular, elastin-like polypeptide assembled in doxorubicin-containing 
nanoparticles of about 20 nm in diameter. Reproduced with permission from [50]. 
(D): Dodecahedral, 16 nm-nanoparticles constructed by self-assembling modular 
peptides  comprising several  tandem architectonic  domains.  Reproduced  with 
permission from [51]. (E): Nanoparticles of around 20 nm constructed by the 
trigonal-WTW modular protein, that comprises three tandem, tryptophane zipper- 
forming peptides. Reproduced with permission from [52]. (F): Nanoparticles 
ranging 20-30 nm formed by branched amphiphilic peptides. Reproduced with 
permission from [53]. (G): Peptide amphiphile nanofibers encapsulating 
camptothecin. Reproduced with permission from [54]. (H): Cryo-Tem image 
reconstruction of the regular human rhinovirus 14 particles bound to different 
molecules of the cell surface receptor ICAM-1. Precise nanoparticle dimensions as 
well as the nature and properties of the building blocks can be found in Table 1. 
Copyrights  are  from  Macmillan  Publishers  Ltd  (2009),  Elsevier  (2006,  2014), 
Royal Society of Chemistry (2011), John Wiley and Sons (1999) and American 
Chemical Society (2011, 2012, 2014).
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Box 1. Nanoparticle-based drug delivery in cancer 
 
 
 
 
Nanotechnology can improve cancer therapy by manipulating the functional 
components of drug vehicles and their architecture and size to ensure adequate 
biodistribution and accumulation in tumor (Figure I). Drug-protein conjugation 
avoids renal filtration by enlarging the drug size over 7 nm and reduces liver 
clearance, especially when blocking phagocytosis by the MPS (for instance by 
PEGylation).   These   effects   determine   a   long   circulation   time   for   the 
nanoconjugate in the bloodstream that improves tumor penetration. In addition, 
active targeting to tumor cells or cancer stem cells (e.g. CXCR4+  cells) promotes 
tumor accumulation and improves the antitumoral effect. This approach allows 
the targeting of cell surface receptors that are overexpressed in tumor cells by 
designing nanoconjugates that incorporate a specific ligand. Specific and 
multivalent binding would be triggering receptor-mediated endocytosis and drug 
release in the cytosol. This strategy promises to achieve high antitumor effect, 
while low drug accumulation and reduced adverse effects in normal tissues as 
compared to the administration of the free drug or plain drug-protein conjugates. 
 
 
 
 
 
Figure 1. Schematic diagram showing how cell-targeted, nanoscale viral mimetics used 
as drug carriers improve drug biodistribution and efficacy in cancer therapy.
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Glossary box 
 
 
Active targeting: Directioning of ligand-driven nanoparticles to tumor cell 
types displaying specific membrane receptors used as targets 
Biodistribution: Map of where compounds or drugs occur in the body of an 
animal or human being upon administration 
Blood circulation time: Time that a nanoconjugate remains detectable in the 
bloodstream 
Cancer stem cells: Cells responsible for maintaining the tumor due to their 
capacity for self-renewal and differentiation 
Cell penetrating peptides: Peptides able to translocate the cell membrane and 
to allow the internalization of associated compounds 
EPR effect: Enhanced permeability and retention of nanoparticles in tumor 
tissue because of their irregularly fenestrated vessels and impaired lymphatic 
drainage 
GRAS: A distinctive label given by the American Food and Drug Administration to 
substances of microorganism to design that their addition to food is safe 
Hepatic clearance: Inactivation of a drug through hepatic metabolism 
MPS: Mononuclear phagocytic system responsible for phagocytosis and 
degradation of particular nanoparticle types 
Nanoconjugate: Therapeutic molecule composed of a drug covalently bound to 
a nanoparticle 
PEGylation: Attaching polyethylene-glycol molecules to nanoparticles to alter 
their physicochemical properties 
Passive targeting: Directioning of nanoparticles to tumors by virtue of the EPR 
 
effect 
 
RGD: Arginine, glycine, and aspartic acid tripeptide frequently used in drug 
delivery and tissue engineering because of its ability to bind certain cell surface 
integrins 
Renal clearance: Elimination from the body of drugs smaller than ˜7 nm, by 
filtration through the kidney 
Trancytosis: Endosomal transport of molecules from one side of the cell to the 
opposite side 
Tumor-homing peptides: Peptides that show high affinity for proteins 
overexpressed at the surface of cancer cells and that are used as agents for drug 
targeting
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Building 
structure 
 
 
or 
block 
self- 
Morphology 
and size 
Example cargo Target                    Ref 
assembling principle 
    
Peptide amphiphiles Fibrils;  100-900 
nm in length. 
Cytotoxic peptides 
(KLAK) 
Transformed cells [55] 
Peptide amphiphiles Nanofibers; 
unidentified 
Camptothecin Human        breast 
cancer                in 
[54] 
 
length 
 
orthotopic      mice 
 
   
models 
 
Branched           peptide 
amphiphiles 
Capsular 
spheres;   10-20 
Radionuclides Not           defined. 
Potential in cancer 
[53] 
 
nm 
 
therapy suggested 
 
Branched           cationic 
peptides 
Capsular 
spheres; 20-500 
Model eosin Y dye Not defined [56] 
 
nm 
   
Self-assembling Planar None described Glioblastoma      in [57] 
peptides fused to PEG nanofibers;  50- 
 
mice models 
 
Table 1. Diversity of engineering strategies to control protein-protein contacts in protein- 
 
based viral mimetics, illustrated by representative examples. 
 
 
 
 
 
 
erences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RGD-containing self- 
assembling peptide 
 
 
Cationic end-terminal 
domains in modular 
proteins 
 
Engineered  E2  subunit 
of pyruvate 
dehydrogenase enzyme 
complex 
400     nm   in
length. 
Single        layer 
nanofibers; 
unidentified 
length 
Regular toroids; 
15-30 nm 
 
 
Hollow 
dodecahedral 
nanoparticles; 
25 nm 
 
 
 
Curcumin                 Hepatic cancer in 
xenograft mice 
models 
 
DNA                          Human   colorectal 
cancer  in 
orthotopic mice 
models 
Doxorubicin             Human        breast 
cancer cells 
 
 
 
[58] 
 
 
 
 
[41;46;48] 
 
 
 
 
[49;59]
Trigonal        tryptophan 
zipper 
Nanospheres; 
20 nm) 
None described Not defined [52] 
Coiled                       coil 
oligomerization 
Polyhedral 
nanoparticles; 
None described Not defined [51] 
domains 16 nm 
   
Cys-rich peptides fused 
to an elastin-like protein 
Nanoparticles; 
20 nm 
Doxorubicin Not           defined. 
Tested    in    mice 
[50] 
   
tumour models 
 
Engineered silk proteins Spheres;     400 
nm 
Doxorubicin Her2- 
overexpressing 
[60] 
   
cultured cells 
 
Human  serum  albumin 
after  denaturation  and 
Nanoparticles; 
120 nm 
Paclitaxel Not           defined. 
Tested     in     H22 
[61] 
further  solubilization 
  
tumor-bearing 
 
   
mice 
 
Self-assembling Nanoparticles; Carboplatin Retinoblastoma [62] 
apotranferrin           and 140    nm    and 
 
cells 
 
lactoferrin 260              nm 
respectively
Folate-conjugated             Nanospheres        Organic                     Several tumor cell   [63]
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bovine serum albumin      255 nm-470 nm   selenocompound      lines 
 
 
PEG: Polyethylene glycol 
 
RGD: Arg-Gly-Asp motif 
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